Rapport Therapeutics, Inc.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $23.76
- 52-Week Range
- $22.06 – $52.93
- Market Cap
- $1.39B
- P/E (TTM)
- —
- EPS (TTM)
- -3.17
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 2.88
- PEG Ratio
- —
- Return on Equity
- -33.33%
- Return on Assets
- -21.96%
- Gross Margin
- -169.58%
- Operating Margin
- -838.08%
- Profit Margin
- 0.00%
- Current Ratio
- 20.07
- Debt/Equity
- 0.02
- Total Debt
- $9.39M
- Free Cash Flow
- $-75.28M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $1.00B
Market Snapshot
About
Rapport Therapeutics, Inc. is a precision neuroscience company developing small molecule medicines for central nervous system disorders, focusing on genetically defined patient populations with high unmet needs.